September 2012, Vol 1, No 4
Personalized Therapy in the Management of Myelodysplastic Syndromes (MDS)
At the 2012 conference of the Global Biomarkers Consortium, which took place March 9-11, 2012, in Orlando, Florida, Gautam Borthakur, MD, from The University of Texas MD Anderson Cancer Center in Houston, Texas, discussed the use of personalized therapy in the management of MDS.
The myelodysplastic syndromes (MDS) are a group of hematopoietic stem cell disorders characterized by ineffective hematopoiesis.1 Interstitial 5q deletions [del(5q)], present in 10% to 15% of patients with MDS, are the most frequent chromosomal abnormalities in MDS.1 MDS progress to acute myeloid leukemia (AML) in about 30% of patients after various intervals from diagnosis and at variable rates.2
- A 40-year-old male US Air Force pilot in excellent health
- Progressive shortness of breath
- Hemoglobin: 7 g/dL
- Platelet count: 800,000/μL
- Absolute neutrophil count: 4000/μL
- Vitamin B12 levels: borderline low
- Started on vitamin B12 injections; hemoglobin improved to 8 g/dL but no further
Bone marrow metaphase analysis
– 11/20 metaphases showed del5 (q13q33)
- Patient was started on lenalidomide at 10 mg/day
- Absolute neutrophil count: 800/μL
- Platelet count: 100,000/μL
- Hemoglobin: 13 g/dL
Cytogenetics: diploid in 3 months
– Fluorescence in situ hybridization negative
After 4.5 years:
– Reemergence of 5q– clone (in 7/20 metaphases)
– Hemoglobin: 13.5 g/dL
– Platelet count: 154/μL
The original International Prognostic Scoring System (IPSS) for MDS, published in 1997 and based on information from 816 patients with MDS, has been used to classify patients with primary, untreated MDS into 1 of 4 risk groups: low risk, intermediate-1, intermediate-2, and high risk regarding the likelihood of survival and progression to AML (Table 1). In this scoring system, risk is determined by the percentage of bone marrow myeloblasts, cytogenetics, and the number of cytopenias. Karyotypic lesions were divided into 3 categories: good [normal, del(5q), del(20q), and –Y], poor (≥3 abnormalities and chromosome 7 anomalies), and intermediate (remaining abnormalities). Cytopenias were defined as a hemoglobin level <10 g/dL, an absolute neutrophil count (ANC) <1500/μL, and a platelet count <100,000/μL. Using this scoring system, patients with lower-risk MDS (ie, low-risk or intermediate-1–risk groups according to the 1997 IPSS) account for approximately 70% of patients with the disease.3 According to the 1997 IPSS, the patient in this case would be classified as low risk, since he had only 1 cytopenia, hemoglobin <10 g/dL, and his karyotype, del(5q), was classified as “good.”
Using this prognostic system, the estimated time to the development of AML was 9.4 years for the low-risk group, 3.3 years for the intermediate-1–risk group, 1.1 years for the intermediate-2–risk group, and 0.2 years for the high-risk group; median survival for the groups were 5.7 years, 3.5 years, 1.2 years, and 0.4 years, respectively (Table 2).3
Since the publication of the IPSS in 1997, knowledge concerning the epidemiology and pathobiology of the MDS, including the prognostic impact of cytogenetic abnormalities, has increased substantially. It is now recognized that the 1997 IPSS oversimplified the true biologic heterogeneity of this group of disorders because it omitted rare abnormalities or combinations of lesions.4 Because of this, new prognostic scoring systems have been proposed. For example, Schanz and colleagues recently published a new comprehensive cytogenetic MDS scoring system based on 2902 patients. In this system, 19 cytogenetic categories were defined and then classified according to 5 prognostic subgroups.5 In addition, a revised IPSS (IPSS-R) has been developed that analyzes MDS patient prognosis more precisely than the initial IPSS by defining 5 rather than the 4 major prognostic categories in the original IPSS and including 5 rather than 3 cytogenetic prognostic subgroups.6 Retained in the IPSS-R are the importance of clinical features, such as cytopenias and percentages of myeloblasts, indicating that although cytogenetics are critical in assessing MDS prognosis and potential for progression to AML, they are only a part of the clinical and laboratory evaluation that determines risk. As with the 1997 IPSS, these newer prognostic systems are applicable only to patients with primary, untreated MDS. However, a research group from the MD Anderson Cancer Center has developed and validated a prognostic scoring system for use in patients with established disease.7,8
According to the most recent guidelines of the National Comprehensive Cancer Network for the treatment of MDS, the patient’s IPSS risk category is used in making therapeutic decisions. The guidelines recommend, “[patients] with del(5q) chromosomal abnormalities and symptomatic anemia should receive lenalidomide.”9
In 2005, the FDA approved lenalidomide, a novel immunomodulatory agent, for use in patients with transfusion-dependent anemia due to low-risk or intermediate-1–risk MDS associated with del(5q) with or without additional cytogenetic abnormalities. The safety and efficacy of lenalidomide were demonstrated in a single-arm, multicenter study in 148 patients with the del(5q) cytogenetic abnormality with or without additional cytogenetic abnormalities.10 Among the 148 patients, 112 (76%) had a reduced need for red blood cell (RBC) transfusions, and 99 (67%) were deemed “transfusion independent,” which was defined as the absence of RBC transfusion during any consecutive “rolling” 56 days (8 weeks) during the treatment period. The median time to response was 4.6 weeks (range, 1-49 weeks). In patients who achieved transfusion independence, the median rise in hemoglobin was 5.4 g/dL (range, 1.1-11.4 g/dL) from baseline. The duration of RBC transfusion independence is shown in Figure 1. Cytogenetic response was assessed by standard metaphase analysis before and after treatment in patients with at least 20 cells in metaphase that could be evaluated in sequential specimens. A complete cytogenetic remission was defined as the absence of cells in metaphase containing any abnormal clone. A partial cytogenetic response was defined as a reduction of at least 50% in the proportion of abnormal cells in metaphase after treatment. Among 85 patients who could be evaluated for cytogenetic responses, 62 (73%) had cytogenetic improvement, and 38 (45%) had a complete cytogenetic remission. The most common grade 3/4 adverse events were neutropenia (54.7%) and thrombocytopenia (43.9%). These results indicate that lenalidomide can overcome the pathogenic effect of del(5q) in MDS and restore bone marrow balance.
Lenalidomide was also studied in 214 patients with transfusion-dependent, low-risk, and intermediate-1–risk MDS who had karyotypes other than del(5q).11 Among these 214 patients, 56 (26%) achieved transfusion independence after a median of 4.8 weeks of treatment. The median duration of transfusion independence was 41.0 weeks. In patients who achieved transfusion independence, the median rise in hemoglobin was 3.2 g/dL (range, 1.0-9.8 g/dL) from baseline. The most common grade 3/4 adverse events were neutropenia (30%) and thrombocytopenia (25%).
The patient in this case was started on lenalidomide 10 mg/day. His ANC and platelet count decreased; his hemoglobin improved. He achieved a complete cytogenetic remission in about 3 months; it was negative by fluorescence in situ hybridization as well. The patient stayed on treatment for about 4.5 years and remained transfusion independent. He actually went back to flying. However, after 4.5 years, the del(5q) returned. His lenalidomide dose was increased to 25 mg/day, and the del(5q) clone size decreased, but the clone never disappeared. Unfortunately, the patient recently returned with full-blown AML with complex cytogenetics in a del(5q) background. Thus, this case illustrates that although lenalidomide is generally effective in patients with low-risk MDS associated with del(5q), it is not curative.
Relationship Between Cytopenias and Response
As shown above in the results from the lenalidomide studies, approximately half of MDS patients with del(5q) and approximately one-fourth of those without del(5q) treated with lenalidomide experience significant cytopenias.
Sekeres and colleagues investigated whether lenalidomide-induced cytopenias that occur early in the treatment course serve as a surrogate marker of clonal suppression and therefore may be predictive of transfusion independence.12 They analyzed 362 low-risk, transfusion-dependent patients with MDS, with or without the del(5q) abnormality, enrolled in the 2 studies described above to determine whether treatment-related cytopenias are correlated with response to lenalidomide. Results showed that among patients with del(5q), 70% of those whose platelet count decreased by ≥50% achieved transfusion independence, compared with 42% of those whose platelet count remained stable or declined by <50% (P=.01). For patients without baseline thrombocytopenia, 75% of patients who experienced a ≥50% decrease in platelet count achieved transfusion independence, compared with 47% of those whose platelet count remained stable or declined <50%; for patients with baseline thrombocytopenia, the numbers were 58% and 33%, respectively (Figure 2).
Among patients without baseline neutropenia, 82% of those whose ANC decreased by ≥75% achieved transfusion independence, compared with 51% whose ANC remained stable or decreased by <75% (P=.02). For patients with baseline neutropenia, treatment-related declines in ANC were not correlated with transfusion- independence response (P=.75). Figure 3 compares patients who developed significant treatment-related neutropenia (ANC decline ≥75%) with those who did not (ANC decline <75%).
No relationship between the development of cytopenias and response could be established for lower-risk patients with MDS without del(5q). The authors concluded that a direct cytotoxic effect of lenalidomide specific to the del(5q) clone may be indicative of a transfusion-independence response.
Unraveling Molecular Abnormalities in MDS
Although specific karyotypic abnormalities have been linked to MDS for decades, recent findings have demonstrated the importance of mutations within individual genes, focal alterations that are not apparent by standard cytogenetics, and aberrant epigenetic regulation of gene expression.13 Bejar and colleagues used a combination of genomic approaches, including next-generation sequencing and mass spectrometry–based genotyping, to identify mutations in samples of bone marrow from 439 patients with MDS. They then examined whether the mutation status for each gene was associated with clinical variables, including specific cytopenias, the proportion of blasts, and overall survival.14 Results showed that somatic point mutations are common in MDS. They identified somatic mutations in 18 genes, including 2, ETV6 and GNAS, that had not previously been reported to be mutated in patients with MDS. A total of 51% of all patients had at least 1 point mutation, including 52% of the patients with normal cytogenetics. Mutations in RUNX1, TP53, and NRAS were most strongly associated with severe thrombocytopenia and an increased proportion of bone marrow blasts. Mutations in 5 genes, TP53, EZH2, ETV6, RUNX1, and ASXL1, were independent prognostic indicators of poor overall survival (Table 3). Nearly one-third of the patients in this study were found to have mutations in 1 or more of the 5 prognostic genes identified.
Papaemmanuil and colleagues identified somatic mutations of the gene encoding RNA splicing factor 3B, subunit 1 (SF3B1), a core component of RNA splicing machinery, in patients with MDS. First, they identified 64 somatically acquired point mutations in 9 patients with low-grade myelodysplasia and found recurrent somatically acquired mutations in SF3B1.15 Targeted resequencing of SF3B1 was performed in a cohort of 2087 patients with myeloid or other cancers. Follow-up revealed SF3B1 mutations in 72 of 354 patients (20%) with MDS, with a particularly high frequency (65%) among patients whose disease was characterized by ring sideroblasts. The observed mutations were less deleterious than was expected on the basis of chance, suggesting that the mutated protein retains structural integrity with altered function. Clinically, patients with SF3B1 mutations had fewer cytopenias and longer event-free survival than patients without SF3B1 mutations.
In a separate study, they set out to further define the clinical significance of these mutations in patients with MDS, myelodysplastic/myeloproliferative neoplasms (MDS/MPN), or acute AML evolving from MDS.16
Somatic mutations of SF3B1 were found in 150 of 533 patients (28.1%) with MDS, 16 of 83 (19.3%) with MDS/MPN, and 2 of 38 (5.3%) with AML. There was a significant association of SF3B1 mutations with the presence of ring sideroblasts (P<.001) and of mutant allele burden with their proportion (P=.002). The mutant gene had a positive predictive value for ring sideroblasts of 97.7% (95% confidence interval, 93.5%-99.5%). In multivariate analysis including established risk factors, SF3B1 mutations were found to be independently associated with better overall survival (hazard ratio, 0.15; P=.025) and lower risk of evolution into AML (hazard ratio, 0.33; P=.049). The close association between SF3B1 mutations and disease phenotype with ring sideroblasts across MDS and MDS/MPN is consistent with a causal relationship. The authors concluded that SF3B1 mutations are independent predictors of favorable clinical outcome, and their incorporation into stratification systems might improve risk assessment in MDS.
Both cytogenetic changes and gene mutations play important roles in the pathogenesis of MDS. Patients with del(5q) have a more favorable prognosis than those without this cytogenetic abnormality, and studies have shown that patients with del(5q) are especially responsive to treatment with lenalidomide. Due to advancements in technology such as whole genome sequencing, the number of known mutations occurring in MDS is steadily increasing.17 Mutations such as TP53, EZH2, ETV6, RUNX1, and ASXL1 have an adverse impact on patient overall survival. SF3B1 mutations, on the other hand, are independent predictors of favorable clinical outcome. Early evidence suggests that specific alterations present in individual patients with MDS can predict prognosis and response to therapy. Bejar and colleagues recently stated, “Elucidation of the full complement of genetic causes of MDS promises profound insight into the biology of the disease, improved classification and prognostic scoring schemes, and the potential for novel targeted therapies with molecular predictors of response.”13
- Giagounidis AA, Germing U, Aul C. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res. 2006;12:5-10.
- National Cancer Institute. Myelodysplastic Syndromes Treatment (PDQ®). General information about myelodysplastic syndromes. www. cancer.gov/cancertopics/pdq/treatment/myelodysplastic/HealthProfessional/page1. Accessed August 23, 2012.
- Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89: 2079-2088.
- Sekeres MA. Myelodysplastic syndromes: it is all in the genes. J Clin Oncol. 2012;30:774-776.
- Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30:820-829.
- 6. Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes [published online ahead of print June 27, 2012]. Blood.
- Kantarjian H, O’Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008; 113:1351-1361.
- Komrokji RS, Corrales-Yepez M, Al Ali N, et al. Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome. Cancer. 2012;118:2659-2664.
- National Comprehensive Cancer Network. NCCN Guidelines Version 2.2013. Myelodysplastic syndromes. www.nccn.org/professionals/physi cian_gls/pdf/mds.pdf. Accessed August 24, 2012.
- List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456-1465.
- 11. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008;111:86-93.
- Sekeres MA, Maciejewski JP, Giagounidis AA, et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2008;26:5943-5949.
- Bejar R, Levine R, Ebert BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol. 2011;29:504-515.
- Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364:2496-2506.
- Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011; 365:1384-1395.
- Malcovati L, Papaemmanuil E, Bowen DT, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/ myeloproliferative neoplasms. Blood. 2011;118:6239-6246.
Schlegelberger B, Göhring G, Thol F, et al. Update on cytogenetic
and molecular changes in myelodysplastic syndromes. Leuk Lymphoma. 2012;53:525-536.
Seattle Genetics is a biotechnology company focused on the development and commercialization of empowered monoclonal antibody–based therapies for the treatment of cancer. Their product, brentuximab vedotin (Adcetris), was granted FDA accelerated approval in August 2011 for 2 indications: the treatment of patients with Hodgkin lymphoma after failure of autologous stem [ Read More ]
Despite increasing publicity, “personalized medicine” is not a new phenomenon in cancer care. Oncologists have long used criteria such as body size, performance status, comorbid conditions, organ function, lifestyle, and a patient’s goals of care to individualize treatment decisions and drug doses. Additionally, dose adjustments of 1 or more agents [ Read More ]